Is WHITE BLOOD CELL COUNT DECREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed WHITE BLOOD CELL COUNT DECREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 30 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported WHITE BLOOD CELL COUNT DECREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and WHITE BLOOD CELL COUNT DECREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause WHITE BLOOD CELL COUNT DECREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes WHITE BLOOD CELL COUNT DECREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if WHITE BLOOD CELL COUNT DECREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing WHITE BLOOD CELL COUNT DECREASED: 30
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where WHITE BLOOD CELL COUNT DECREASED is a reported side effect: 0.9012%

FDA reports of any drug causing WHITE BLOOD CELL COUNT DECREASED : 27859
Average percentage for all medicated patients where WHITE BLOOD CELL COUNT DECREASED is reported as a complication: 0.1746%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with WHITE BLOOD CELL COUNT DECREASED:

CLOZARIL (2374 patients)
PEGASYS (2199 patients)
RIBAVIRIN (2009 patients)
REVLIMID (1800 patients)
PREDNISOLONE (1433 patients)
ASPIRIN (1371 patients)
CYCLOPHOSPHAMIDE (1215 patients)
GLEEVEC (1129 patients)
COPEGUS (1083 patients)
DECADRON (1065 patients)
LASIX (1023 patients)
PEG-INTRON (1003 patients)
CISPLATIN (946 patients)
CARBOPLATIN (927 patients)
DEXAMETHASONE (921 patients)
CLOZAPINE (885 patients)
METHOTREXATE (860 patients)
FLUOROURACIL (846 patients)
ZOMETA (814 patients)
ALLOPURINOL (801 patients)
PREDNISONE (779 patients)
REBETOL (774 patients)
OMEPRAZOLE (771 patients)
SEROQUEL (708 patients)
NEUPOGEN (668 patients)
DOXORUBICIN HCL (660 patients)
FAMOTIDINE (649 patients)
FOLIC ACID (626 patients)
ENBREL (618 patients)
ACETAMINOPHEN (588 patients)
TAXOL (573 patients)
LANSOPRAZOLE (572 patients)
VELCADE (567 patients)
SOLIRIS (555 patients)
ZYPREXA (552 patients)
TAXOTERE (540 patients)
ACYCLOVIR (534 patients)
ETOPOSIDE (534 patients)
AVONEX (529 patients)
EXJADE (522 patients)
SYNTHROID (520 patients)
NEXAVAR (500 patients)
OXYCONTIN (497 patients)
GEMZAR (494 patients)
REBIF (491 patients)
FUROSEMIDE (484 patients)
NORVASC (482 patients)
LIPITOR (480 patients)
CYTARABINE (480 patients)
PREDONINE (476 patients)
FLUCONAZOLE (476 patients)
ZOFRAN (475 patients)
RIBASPHERE (463 patients)
LISINOPRIL (460 patients)
MAGNESIUM OXIDE (460 patients)
LEVOTHYROXINE SODIUM (460 patients)
RISPERDAL (458 patients)
AVASTIN (440 patients)
LOXONIN (436 patients)
REMICADE (435 patients)
HUMIRA (433 patients)
ATIVAN (422 patients)
NEURONTIN (419 patients)
GILENYA (418 patients)
NEULASTA (416 patients)
RITUXAN (413 patients)
COUMADIN (409 patients)
NEXIUM (407 patients)
ATENOLOL (407 patients)
DIFLUCAN (402 patients)
GABAPENTIN (399 patients)
MYLOTARG (387 patients)
VINCRISTINE (387 patients)
MUCOSTA (385 patients)
FOSAMAX (385 patients)
RITUXIMAB (384 patients)
PROTONIX (383 patients)
KYTRIL (383 patients)
AMBIEN (380 patients)
LORAZEPAM (379 patients)
TELAVIC (TELAPREVIR) (378 patients)
DIOVAN (377 patients)
SUTENT (376 patients)
NEORAL (375 patients)
PACLITAXEL (375 patients)
TEGRETOL (373 patients)
LEVOFLOXACIN (367 patients)
SIMVASTATIN (354 patients)
IBUPROFEN (352 patients)
PREDNISONE TAB (352 patients)
BACTRIM (334 patients)
COMPAZINE (333 patients)
VANCOMYCIN (327 patients)
CYCLOSPORINE (326 patients)
PRILOSEC (324 patients)
KEPPRA (321 patients)
PEG-INTERFERON A-2A (RO 25-8310) (317 patients)
POTASSIUM CHLORIDE (316 patients)
LAMICTAL (315 patients)
ZOLOFT (314 patients)
PEGINTERFERON ALFA-2A (313 patients)
XANAX (312 patients)
CLONAZEPAM (311 patients)
OXALIPLATIN (310 patients)
VITAMIN D (305 patients)
OXYCODONE HCL (302 patients)
ZANTAC (300 patients)
LEXAPRO (300 patients)
VALPROATE SODIUM (292 patients)
DIAZEPAM (289 patients)
WARFARIN SODIUM (287 patients)
VIDAZA (285 patients)
DEXAMETHASONE TAB (284 patients)
MORPHINE (278 patients)
HYDROCHLOROTHIAZIDE (277 patients)
BENDAMUSTINE HCL (277 patients)
PEGINTERFERON ALFA-2B (275 patients)
PROGRAF (274 patients)
SULFAMETHOXAZOLE AND TRIMETHOPRIM (274 patients)
AMLODIPINE (274 patients)
OLANZAPINE (272 patients)
LYRICA (271 patients)
BEVACIZUMAB (270 patients)
TOCILIZUMAB (269 patients)
RADIATION THERAPY (268 patients)
PAXIL (266 patients)
MAGMITT (264 patients)
CELLCEPT (263 patients)
URSO 250 (261 patients)
MYCOPHENOLATE MOFETIL (258 patients)
ACTEMRA (258 patients)
DOXORUBICIN HYDROCHLORIDE (256 patients)
ARANESP (255 patients)
PROCRIT (255 patients)
HERCEPTIN (253 patients)
BENADRYL (253 patients)
MIRTAZAPINE (252 patients)
DEPAKOTE (251 patients)
TASIGNA (249 patients)
LEUCOVORIN CALCIUM (248 patients)
XELODA (248 patients)
RABEPRAZOLE SODIUM (246 patients)
LEVAQUIN (246 patients)
INCIVEK (238 patients)
ALDACTONE (238 patients)
CIPROFLOXACIN (238 patients)
VITAMIN B-12 (238 patients)
VOLTAREN (234 patients)
VALTREX (233 patients)
METFORMIN HCL (233 patients)
PLAVIX (231 patients)
TOPROL-XL (230 patients)
DOCETAXEL (229 patients)
SOLU-MEDROL (228 patients)
PREVACID (226 patients)
CALCIUM (226 patients)
ZOCOR (223 patients)
ONDANSETRON (222 patients)
SELBEX (220 patients)
MYCOPHENOLATE MOFETIL (CELLCEPT) (211 patients)
VICODIN (211 patients)
CELEBREX (210 patients)
AREDIA (209 patients)
ERBITUX (208 patients)
NEUTROGIN (207 patients)
ALIMTA (205 patients)
TAKEPRON (205 patients)
THALOMID (204 patients)
BAKTAR (204 patients)
CAPECITABINE (203 patients)
ITRACONAZOLE (203 patients)
DEXAMETHASONE SODIUM PHOSPHATE (202 patients)
PERCOCET (201 patients)
ALBUTEROL (199 patients)
INSULIN (198 patients)
METHYLPREDNISOLONE (197 patients)
BACLOFEN (196 patients)
VINCRISTINE SULFATE (196 patients)
THYMOGLOBULIN (196 patients)
RAMIPRIL (195 patients)
PURSENNID (193 patients)
SUNITINIB MALATE (193 patients)
RHEUMATREX (193 patients)
METOPROLOL TARTRATE (192 patients)
MULTI-VITAMIN (192 patients)
LAMOTRIGINE (191 patients)
TACROLIMUS (191 patients)
DURAGESIC-100 (191 patients)
IRINOTECAN HCL (190 patients)
ABRAXANE (190 patients)
ACCUTANE (190 patients)
CYMBALTA (189 patients)
GEMCITABINE (188 patients)
DIGOXIN (185 patients)
LACTULOSE (185 patients)
TYSABRI (184 patients)
RISPERIDONE (184 patients)
CLARITHROMYCIN (183 patients)
PLATELETS (179 patients)
GASTER (178 patients)
ALPRAZOLAM (178 patients)
KLONOPIN (176 patients)
CITALOPRAM HYDROBROMIDE (175 patients)
METOCLOPRAMIDE (174 patients)
CYANOCOBALAMIN (172 patients)
FILGRASTIM (171 patients)
ACTOS (170 patients)
MULTI-VITAMINS (169 patients)
PEMETREXED (168 patients)
SPRYCEL (168 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about WHITE BLOOD CELL COUNT DECREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.